Novartis, Celgene Hit Teva Again Over ADHD Drug Patents
Celgene Corp. and Novartis AG recently hit Teva Pharmaceuticals USA Inc. with a fresh patent infringement suit in New Jersey over Teva's plan to market a generic version of attention deficit...To view the full article, register now.
Already a subscriber? Click here to view full article